IOG PEN Retatrutide 10MG
Convenient and precise insulin delivery device
$200.00
Description
Retatrutide is
an investigational weight loss drug in development that has shown significant weight reduction in phase 2 clinical trials by mimicking three key hormones involved in appetite and metabolism. It is not yet approved by the Food and Drug Administration (FDA).
How retatrutide works for weight loss
Retatrutide is a “triple agonist,” meaning it activates receptors for three different hormones to promote weight loss and improve metabolic health.
GLP-1 (glucagon-like peptide-1): Slows down the emptying of the stomach to help you feel fuller for longer.
GIP (glucose-dependent insulinotropic polypeptide): Supports insulin release after eating and helps the body process fat more efficiently.
Glucagon: Increases the body’s energy expenditure by encouraging it to burn stored fat.
Weight loss results from clinical trials
A 48-week phase 2 clinical trial involving adults with obesity demonstrated the following dose-dependent results:
Average weight loss: At the highest dose (12 mg), participants achieved an average weight loss of 24.2%. Those on the 8 mg dose lost an average of 22.8% of their body weight.
Significant weight loss achievements: 83% of participants on the 12 mg dose lost 15% or more of their body weight, and 26% lost 30% or more.
Retatrutide vs. other weight loss drugs
Retatrutide’s triple-action mechanism may give it an edge over existing weight loss medications.
Semaglutide (Wegovy, Ozempic): A single agonist that targets only the GLP-1 receptor.
Tirzepatide (Zepbound, Mounjaro): A dual agonist that targets both the GLP-1 and GIP receptors.
While tirzepatide has produced very strong weight loss results in its own trials (up to 21% after 72 weeks), retatrutide’s phase 2 results suggest it may be more effective over a shorter period. However, a direct, head-to-head comparison in a large phase 3 trial has not yet been completed.
